VOLUNTARY ANNOUNCEMENT - JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that JMT106 (the ‘‘Product ’’), a bispecific fusion protein drug developed by the Group, has o btained approval from the National Medical Products Administration of the People ’s Republic of China to conduct clinical trials in China. The Product was also approved by the U.S. Food and Drug Admini stration (FDA) in January 2024 to conduct clinical trials in the U.S. The Product is a bispecific fusion protein drug that targets GPC3 and interferon receptors, killing tumor cells through GPC3-targeted antibodies while simultaneou sly activating immune regulation of the tumor microenvironment mediated by interferon receptors. GPC3 i s specifically and highly expressed in various solid tumors such as hepatocellular carcinoma, squ amous cell carcinoma of the lung and ovarian cancer. The indication for this clinical trial appr oval is advanced solid tumors. Preclinical studies demonstrated that the Product had a broad variety of indications with significant anti-tumor effects and a good safety profile in multiple malignant tumo r models, providing a promising clinical development value. By order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 19 May 2025 As at the date of this announcement, the Board comprises Mr. C AI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chu nlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and M r. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

The release as fetched from its publisher. irasia.com ↗